前列腺癌的分子影像学：正电子发射断层扫描放射性示踪剂。
Molecular imaging of prostate cancer: PET radiotracers.
机构信息
Department of Radiology, Keck School of Medicine of USC, University of Southern California, 2250 Alcazar St, CSC 102, Los Angeles, CA 90033, USA.
出版信息
AJR Am J Roentgenol. 2012 Aug;199(2):278-91. doi: 10.2214/AJR.12.8816.
Abstract
OBJECTIVE
Recent advances in the fundamental understanding of the complex biology of prostate cancer have provided an increasing number of potential targets for imaging and treatment. The imaging evaluation of prostate cancer needs to be tailored to the various phases of this remarkably heterogeneous disease.
CONCLUSION
In this article, I review the current state of affairs on a range of PET radiotracers for potential use in the imaging evaluation of men with prostate cancer.
摘要
目的
近年来，人们对前列腺癌复杂生物学的基础认识取得了进展，为成像和治疗提供了越来越多的潜在靶点。前列腺癌的影像学评估需要根据这种显著异质性疾病的各个阶段进行调整。
结论
在本文中，我回顾了一系列正电子发射断层扫描（PET）放射性示踪剂在评估男性前列腺癌中的潜在应用的现状。
相似文献
1
Molecular imaging of prostate cancer: PET radiotracers.前列腺癌的分子影像学：正电子发射断层扫描放射性示踪剂。
AJR Am J Roentgenol. 2012 Aug;199(2):278-91. doi: 10.2214/AJR.12.8816.
2
More advantages in detecting bone and soft tissue metastases from prostate cancer using F-PSMA PET/CT.使用F-PSMA PET/CT检测前列腺癌骨和软组织转移方面有更多优势。
Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7.
3
Clinical PET Imaging in Prostate Cancer.前列腺癌的临床正电子发射断层显像
Radiographics. 2017 Sep-Oct;37(5):1512-1536. doi: 10.1148/rg.2017170035. Epub 2017 Aug 11.
4
Positron emission tomography in imaging evaluation of staging, restaging, treatment response, and prognosis in prostate cancer.正电子发射断层扫描在前列腺癌分期、再分期、治疗反应和预后评估中的应用。
Abdom Radiol (NY). 2016 May;41(5):889-98. doi: 10.1007/s00261-015-0563-0.
5
Molecular imaging of prostate cancer with PET.正电子发射断层扫描在前列腺癌中的分子影像学研究。
J Nucl Med. 2013 Oct;54(10):1685-8. doi: 10.2967/jnumed.113.126094.
6
Prostate cancer.前列腺癌
Methods Mol Biol. 2011;727:265-90. doi: 10.1007/978-1-61779-062-1_15.
7
Clinical Applications of Molecular Imaging in the Management of Prostate Cancer.分子成像在前列腺癌管理中的临床应用
PET Clin. 2017 Apr;12(2):185-192. doi: 10.1016/j.cpet.2016.11.001. Epub 2017 Jan 16.
8
Update on PET radiopharmaceuticals: life beyond fluorodeoxyglucose.正电子发射断层显像（PET）放射性药物的最新进展：氟脱氧葡萄糖之外的发展
Radiol Clin North Am. 2004 Nov;42(6):1033-53, viii. doi: 10.1016/j.rcl.2004.08.009.
9
[Multimodality MRI and PET for restaging prostate cancer after biochemical failure of the treatment].[多模态磁共振成像和正电子发射断层扫描用于治疗生化失败后前列腺癌的再分期]
Cancer Radiother. 2014 Oct;18(5-6):509-16. doi: 10.1016/j.canrad.2014.07.148. Epub 2014 Sep 4.
10
Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline.前列腺癌：18F-FDG、18F-或 11C-乙酸盐、18F-或 11C-胆碱的 PET 成像。
J Nucl Med. 2011 Jan;52(1):81-9. doi: 10.2967/jnumed.110.077941. Epub 2010 Dec 13.
引用本文的文献
1
Positron Emission Tomography Radiotracers for Identification of Site of Recurrence in Prostate Cancer After Primary Treatment Failure.用于识别前列腺癌初次治疗失败后复发部位的正电子发射断层显像放射性示踪剂
Cancers (Basel). 2025 May 21;17(10):1723. doi: 10.3390/cancers17101723.
2
Advancements in molecular imaging probes for precision diagnosis and treatment of prostate cancer.用于前列腺癌精准诊断与治疗的分子成像探针的进展。
J Zhejiang Univ Sci B. 2025 Jan 15;26(2):124-144. doi: 10.1631/jzus.B2300614.
3
Diagnostic Accuracy of Molecular Imaging Techniques for Detecting Prostate Cancer: A Systematic Review.分子成像技术检测前列腺癌的诊断准确性：一项系统评价。
Diagnostics (Basel). 2024 Jun 21;14(13):1315. doi: 10.3390/diagnostics14131315.
4
From biology to the clinic - exploring liver metastasis in prostate cancer.从生物学到临床 - 探索前列腺癌中的肝转移。
Nat Rev Urol. 2024 Oct;21(10):593-614. doi: 10.1038/s41585-024-00875-x. Epub 2024 Apr 26.
5
An Overview of In Vitro Assays of Cu-, Ga-, I-, and Tc-Labelled Radiopharmaceuticals Using Radiometric Counters in the Era of Radiotheranostics.放射治疗诊断时代使用放射性计数器对铜、镓、碘和锝标记的放射性药物进行体外分析概述。
Diagnostics (Basel). 2023 Mar 23;13(7):1210. doi: 10.3390/diagnostics13071210.
6
Molecular Imaging in Primary Staging of Prostate Cancer Patients: Current Aspects and Future Trends.前列腺癌患者初始分期中的分子成像：当前现状与未来趋势
Cancers (Basel). 2021 Oct 26;13(21):5360. doi: 10.3390/cancers13215360.
7
The Evolving Role of F-FDG PET/CT in Diagnosis and Prognosis Prediction in Progressive Prostate Cancer.F-FDG PET/CT在进展期前列腺癌诊断及预后预测中的作用演变
Front Oncol. 2021 Jul 29;11:683793. doi: 10.3389/fonc.2021.683793. eCollection 2021.
8
Effects of administration route on uptake kinetics of F-sodium fluoride positron emission tomography in mice.给药途径对 F-氟[18F]酸钠正电子发射断层显像在小鼠体内摄取动力学的影响。
Sci Rep. 2021 Mar 9;11(1):5512. doi: 10.1038/s41598-021-85073-0.
9
Comparison of prostate-specific membrane antigen ligands in clinical translation research for diagnosis of prostate cancer.比较用于前列腺癌诊断的临床转化研究中的前列腺特异性膜抗原配体。
Cancer Rep (Hoboken). 2019 Aug;2(4):e1169. doi: 10.1002/cnr2.1169. Epub 2019 Apr 2.
10
A review of prostate cancer imaging, positron emission tomography, and radiopharmaceutical-based therapy.前列腺癌成像、正电子发射断层扫描及放射性药物治疗综述。
Can Urol Assoc J. 2020 Apr;14(4):130-138. doi: 10.5489/cuaj.6506. Epub 2020 Apr 1.
本文引用的文献
1
2
Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer.前瞻性评估 18F-NaF 和 18F-FDG PET/CT 在前列腺癌生化复发后隐匿性转移病灶检测中的应用。
Clin Nucl Med. 2012 Jul;37(7):637-43. doi: 10.1097/RLU.0b013e318252d829.
3
In vitro and in vivo evaluation of a 64Cu-labeled NOTA-Bn-SCN-Aoc-bombesin analogue in gastrin-releasing peptide receptor expressing prostate cancer.在表达胃泌素释放肽受体的前列腺癌中进行 64Cu 标记的 NOTA-Bn-SCN-Aoc-bombesin 类似物的体外和体内评价。
Nucl Med Biol. 2012 Jul;39(5):609-16. doi: 10.1016/j.nucmedbio.2011.12.004. Epub 2012 Jan 20.
4
Influence of PSA, PSA velocity and PSA doubling time on contrast-enhanced 18F-choline PET/CT detection rate in patients with rising PSA after radical prostatectomy.根治性前列腺切除术后 PSA 升高患者中 PSA、PSA 速度和 PSA 倍增时间对 18F-胆碱 PET/CT 增强检测率的影响。
Eur J Nucl Med Mol Imaging. 2012 Apr;39(4):589-96. doi: 10.1007/s00259-011-2030-7. Epub 2012 Jan 10.
5
6
Novel molecular targets for the therapy of castration-resistant prostate cancer.用于去势抵抗性前列腺癌治疗的新型分子靶标。
Eur Urol. 2012 May;61(5):950-60. doi: 10.1016/j.eururo.2011.12.028. Epub 2011 Dec 22.
7
Relationship between PSA kinetics and [18F]fluorocholine PET/CT detection rates of recurrence in patients with prostate cancer after total prostatectomy.根治性前列腺切除术后前列腺癌患者 PSA 动力学与 [18F]氟胆碱 PET/CT 复发检测率的关系。
Eur J Nucl Med Mol Imaging. 2012 Feb;39(2):271-82. doi: 10.1007/s00259-011-1970-2. Epub 2011 Nov 16.
8
Evaluation of primary prostate cancer using 11C-methionine-PET/CT and 18F-FDG-PET/CT.使用 11C-蛋氨酸-PET/CT 和 18F-FDG-PET/CT 评估原发性前列腺癌。
Ann Nucl Med. 2012 Feb;26(2):138-45. doi: 10.1007/s12149-011-0551-6. Epub 2011 Nov 9.
9
2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer.2-(3-{1-羧基-5-[(6-[18F]氟吡啶-3-羰基)-氨基]-戊基}-脲基)-戊二酸，[18F]DCFPyL，一种用于前列腺癌的 PSMA 基 PET 成像剂。
Clin Cancer Res. 2011 Dec 15;17(24):7645-53. doi: 10.1158/1078-0432.CCR-11-1357. Epub 2011 Oct 31.
10
Use of [11C]choline PET-CT as a noninvasive method for detecting pelvic lymph node status from prostate cancer and relationship with choline kinase expression.使用[11C]胆碱 PET-CT 作为一种非侵入性方法，用于检测前列腺癌的盆腔淋巴结状态及其与胆碱激酶表达的关系。
Clin Cancer Res. 2011 Dec 15;17(24):7673-83. doi: 10.1158/1078-0432.CCR-11-2048. Epub 2011 Oct 28.
Zotero 插件